Short answer
GeneDx Holdings Corp. (WGS) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results cover quarter ended March 31, 2026; press release and earnings presentation furnished as Exhibits 99.1 and 99.3.
GeneDx Holdings Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results cover quarter ended March 31, 2026; press release and earnings presentation furnished as Exhibits 99.1 and 99.3
- Selling and marketing combined with general and administrative into “selling, general and administrative”
- Presentation change has no impact on previously reported GAAP results
- Adjusted net income methodology now excludes non-core lease costs from vacant Connecticut facilities
- 2025 and interim-period figures recast for comparability; changes are not a GAAP restatement
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $102.3M, up 17% YoY, while exome/genome revenue grew 27% to $90.6M
- Exome/genome volumes rose 34% to 27,488 tests, signaling demand strength despite revenue underperformance
- Adjusted net loss $8.2M versus $9.2M income, with GAAP net loss $63.3M including $31.3M impairment
- Full-year revenue guidance cut to $475–$490M from $540–$555M, while volume growth remains at least 30%
- Cash, securities and restricted cash $171.7M; operating cash burn reached $32.4M in Q1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GeneDx Holdings Corp. 8-K filings
Get the next WGS 8-K as it lands
Follow WGS for push alerts, or ask the research agent what this filing means.